Project Grant R37CA304431
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $702K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10010, USA
Similar Awards
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded New York University $169,500 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of LINE-1 retrotransposons in human diseases by mining patient data from the NYU Langone database, which comprises approximately 4.8 million patient records. The research will analyze reverse transcriptase inhibitor-treated patient cohorts against control cohorts to identify differences in disease incidence, integrating...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded New York University $687,490 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mitochondrial genetics as a clinical predictor of treatment response in melanoma patients receiving neoadjuvant immune checkpoint inhibition therapy. The research addresses a significant clinical gap: more than 40 percent of melanoma patients fail to respond to immune checkpoint inhibitor combinations. The award funds investigation of...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $695,154 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate inter-individual phenotypes of cancer gene mutation susceptibility in the human airway. The award funds research defining how somatic mutations accumulate differently across individuals in lung cancer-relevant genes, with focus on early-stage driver mutations in normal bronchial...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $524,110 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Listing Project Grant R01CA314254). The award funds research on one-ended break repair mechanisms in mammalian cells, specifically investigating how cells repair DNA damage at broken replication forks and double-strand...
- The National Institutes of Health National Cancer Institute awarded Weill Medical College of Cornell University $198,164 on September 26, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research into genomic instability mechanisms in lung cancer driven by the APOBEC3 family of cytosine deaminases. The award funds investigation of APOBEC3 (A3) mutagenesis in lung adenocarcinoma, with research activities centered on identifying which specific A3 family members...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $681,818 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research into restoring anti-tumor immunity in chromosomally unstable tumors. The research addresses chromosomal instability (CIN)—frequent chromosome missegregation during mitosis—as a genomic hallmark of solid tumors that correlates with immune evasion and resistance to immunotherapies. The project...
- The National Cancer Institute awarded New York University $149,190 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training in biomedical careers fundamental to the National Cancer Program. The recipient, doing business as New York University School of Medicine, will conduct mechanistic research on DNA methylation and its regulation by epigenetic histone modifications. The research addresses cancer-related aberrations in DNA methylation...